Take Advantage of Using HSA and FSA Accounts at Our Clinics
At AquaVitae, we’re committed to keeping you informed about the latest advancements in health and wellness. One exciting development in recent medical research involves the potential brain-protective benefits of Ozempic and other Semaglutide/GLP-1-based medications, commonly used for type 2 diabetes and weight management. Emerging studies suggest these drugs may do more than regulate blood sugar and promote weight loss—they could also help protect your brain from stroke and improve recovery outcomes. Here’s what you need to know about this promising new research.
What Are Ozempic and Semaglutide/GLP-1?
Ozempic, along with its counterpart Wegovy, contains Semaglutide/GLP-1, a glucagon-like peptide-1 (GLP-1) receptor agonist. These medications mimic the GLP-1 hormone, which helps regulate blood sugar, slow digestion, and reduce appetite. Originally developed to manage type 2 diabetes, Ozempic has gained attention for its weight loss benefits and, more recently, its potential to support cardiovascular and brain health.
The Link Between Semaglutide/GLP-1 and Stroke Protection
Stroke remains one of the leading causes of disability and death worldwide, often linked to risk factors like obesity, diabetes, high blood pressure, and inflammation. Recent studies, including three presented at the Society of NeuroInterventional Surgery’s (SNIS) 22nd Annual Meeting in 2025, have explored whether Semaglutide/GLP-1 could reduce stroke risk or improve outcomes after a stroke. Here’s a closer look at the findings:
1. Lower Stroke Mortality Rates
A study led by researchers at the University of Wisconsin-Madison analyzed data from over 2 million stroke patients, including 43,338 on Ozempic, and a smaller cohort from their medical center. The results were striking: only 5.26% of Ozempic users died from their strokes compared to 21.61% of non-users in the global dataset. Long-term survival was also significantly better, with 77.5% of Ozempic users surviving compared to 30.95% of non-users. The university’s data echoed these findings, showing a mortality rate of 5.26% for Ozempic users versus 26.57% for non-users. These results suggest that Semaglutide/GLP-1 may offer a protective effect during acute ischemic strokes (strokes caused by blocked blood vessels).
2. Reduced Stroke Risk
A second study from the same team examined emergency department records and found that patients likely using Ozempic had a lower risk of stroke. While the study relied on indirect data (medical codes suggesting Ozempic use), the trend toward reduced stroke odds is encouraging. Researchers recommend further studies using pharmacy records to confirm these findings, but the initial data points to a potential preventive role for Semaglutide/GLP-1.
3. Improved Recovery After Stroke and Brain Hemorrhage
A third study, conducted by the University of Texas Medical Branch, investigated Semaglutide/GLP-1’s effects on both ischemic strokes and brain hemorrhages (bleeds caused by ruptured vessels or aneurysms). By reviewing patient records at 6 and 12 months post-hemorrhage and 1 and 2 years post-stroke, researchers found that GLP-1 receptor agonists like Ozempic were linked to reduced risks of cognitive side effects, seizures, future brain hemorrhages, and death. This suggests Semaglutide/GLP-1 may not only help prevent strokes but also improve long-term recovery by protecting brain function.
How Does Semaglutide/GLP-1 Protect the Brain?
While more research is needed to fully understand the mechanisms, experts propose several ways Semaglutide/GLP-1 may benefit brain health:
- Weight Loss and Metabolic Health: Obesity and type 2 diabetes are major stroke risk factors. By promoting weight loss and improving blood sugar control, Semaglutide/GLP-1 reduces strain on blood vessels and lowers the risk of blockages or ruptures.
- Anti-Inflammatory Effects: Semaglutide/GLP-1 may reduce inflammation in the body and brain, which can contribute to plaque buildup and blood vessel damage. Lower inflammation may stabilize arteries and reduce the likelihood of stroke-causing blockages.
- Neuroprotection: Animal studies suggest Semaglutide/GLP-1 protects neurons (brain cells responsible for memory and movement) by reducing oxidative stress, inflammation, and cell death (ferroptosis). These effects could explain improved recovery outcomes and reduced cognitive decline after stroke.
- Cardiovascular Benefits: Semaglutide/GLP-1 has been shown to lower the risk of cardiovascular events like heart attacks and strokes by 20% in people with obesity and pre-existing cardiovascular disease. Better heart health supports better brain health, as the two are closely connected.
What This Means for You
If you’re managing type 2 diabetes or obesity, Semaglutide/GLP-1-based medications may offer benefits beyond weight loss and blood sugar control. The potential to reduce stroke risk and improve recovery outcomes is an exciting development, especially for those with a history of cardiovascular disease or stroke risk factors like high blood pressure or high cholesterol.
Even if you don’t have heart disease or diabetes, Semaglutide/GLP-1 can have a positive effect on several contributors to stroke risk. Examples of these include blood glucose (sugar) levels, body weight, inflammation, blood pressure, and cholesterol.
However, these medications are not for everyone. Side effects like nausea and upset stomach are possible, and Ozempic is typically prescribed only for those with type 2 diabetes or obesity. Other GLP-1 plans might be good alternative options. Always consult your healthcare provider to discuss whether Semaglutide/GLP-1 is right for you and to explore other stroke prevention strategies, such as a healthy diet, regular exercise, and managing blood pressure and cholesterol.
The Road Ahead: More Research Needed
While these findings are promising, researchers emphasize the need for further studies to confirm Semaglutide/GLP-1’s stroke-protective effects. Clinical trials are underway to explore its role in preventing cognitive decline, Alzheimer’s disease, and other brain-related conditions. At Aquavitality.com, we’re closely following these developments to bring you the most up-to-date care options.
“More research is certainly needed, but seeing the potential protection offered by these medications is a fascinating finding,” said Ahmed Elbayomy (University of Wisconsin, Madison, USA), primary author for two of these studies, also describing the results as “very promising”.
Take Control of Your Brain Health
Stroke prevention starts with understanding your risk factors and making informed choices. At AquaVitae, our team is here to help you navigate your health journey, whether through lifestyle changes, medication options like Wegovy and Semaglutide/GLP-1, or comprehensive stroke risk assessments. Contact us today to schedule an appointment and learn how we can support your brain and heart health.
Disclaimer: Always consult with a healthcare professional before starting or changing any medication. The studies discussed are preliminary, and more research is needed to confirm Semaglutide/GLP-1’s effects on stroke prevention and recovery.
Other Sources: Studies presented at the Society of NeuroInterventional Surgery’s 22nd Annual Meeting (2025), University of Wisconsin-Madison, University of Texas Medical Branch, and preclinical research published in PMC (2024).
https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.037775
https://www.goodrx.com/classes/glp-1-agonists/Semaglutide/GLP-1-and-stroke-risk
